WO2004064866A1 - カルノシナーゼ阻害剤とl−カルノシン類との併用および組成物 - Google Patents
カルノシナーゼ阻害剤とl−カルノシン類との併用および組成物 Download PDFInfo
- Publication number
- WO2004064866A1 WO2004064866A1 PCT/JP2004/000351 JP2004000351W WO2004064866A1 WO 2004064866 A1 WO2004064866 A1 WO 2004064866A1 JP 2004000351 W JP2004000351 W JP 2004000351W WO 2004064866 A1 WO2004064866 A1 WO 2004064866A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lunosine
- alanine
- carnosine
- derivative
- carnosinase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 70
- 108010071840 Cytosol nonspecific dipeptidase Proteins 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 241000124008 Mammalia Species 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 230000036541 health Effects 0.000 claims abstract description 9
- 108010087806 Carnosine Proteins 0.000 claims description 73
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 73
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 29
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 20
- 229940044199 carnosine Drugs 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 17
- -1 L-Valenin Chemical compound 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 16
- 229910052751 metal Inorganic materials 0.000 claims description 16
- 239000002184 metal Substances 0.000 claims description 16
- 229940088594 vitamin Drugs 0.000 claims description 15
- 229930003231 vitamin Natural products 0.000 claims description 15
- 239000011782 vitamin Substances 0.000 claims description 15
- 235000013343 vitamin Nutrition 0.000 claims description 15
- 150000003862 amino acid derivatives Chemical class 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 239000002738 chelating agent Substances 0.000 claims description 13
- 239000003638 chemical reducing agent Substances 0.000 claims description 13
- 230000002209 hydrophobic effect Effects 0.000 claims description 13
- 229910001437 manganese ion Inorganic materials 0.000 claims description 13
- 241000282412 Homo Species 0.000 claims description 12
- CCLQKVKJOGVQLU-QMMMGPOBSA-N L-homocarnosine Chemical compound NCCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 CCLQKVKJOGVQLU-QMMMGPOBSA-N 0.000 claims description 12
- 235000013334 alcoholic beverage Nutrition 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 12
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 11
- 229940000635 beta-alanine Drugs 0.000 claims description 10
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims description 9
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 claims description 8
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims description 7
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 claims description 6
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 229950009811 ubenimex Drugs 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 108700002498 homocarnosine Proteins 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 6
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
- 230000036559 skin health Effects 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- 230000035622 drinking Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229960003767 alanine Drugs 0.000 description 34
- 210000001519 tissue Anatomy 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 23
- 210000003205 muscle Anatomy 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 230000032683 aging Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 239000003963 antioxidant agent Substances 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000005445 natural material Substances 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 235000013522 vodka Nutrition 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 150000002430 hydrocarbons Chemical group 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 229960002885 histidine Drugs 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000037147 athletic performance Effects 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 239000011572 manganese Substances 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 206010003805 Autism Diseases 0.000 description 3
- 208000020706 Autistic disease Diseases 0.000 description 3
- 102100031006 Beta-Ala-His dipeptidase Human genes 0.000 description 3
- 108030007222 Carnosine synthases Proteins 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000919694 Homo sapiens Beta-Ala-His dipeptidase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- ANRUJJLGVODXIK-UHFFFAOYSA-N 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide Chemical compound NCCC(=O)NCCC1=CN=CN1 ANRUJJLGVODXIK-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010049565 Muscle fatigue Diseases 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 108700021352 carcinine Proteins 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 229940114081 cinnamate Drugs 0.000 description 2
- 235000020057 cognac Nutrition 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- 235000015041 whisky Nutrition 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- GUIBZZYABLMRRD-CQSZACIVSA-N (2r)-4,8-dimethoxy-9-methyl-2-propan-2-yl-2,3-dihydrofuro[2,3-b]quinolin-9-ium Chemical compound C[N+]1=C2C(OC)=CC=CC2=C(OC)C2=C1O[C@@H](C(C)C)C2 GUIBZZYABLMRRD-CQSZACIVSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- JLVSRWOIZZXQAD-UHFFFAOYSA-N 2,3-disulfanylpropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(S)CS JLVSRWOIZZXQAD-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- MCRZWYDXIGCFKO-UHFFFAOYSA-N 2-butylpropanedioic acid Chemical compound CCCCC(C(O)=O)C(O)=O MCRZWYDXIGCFKO-UHFFFAOYSA-N 0.000 description 1
- HXYUWNUJDSMLIE-UHFFFAOYSA-N 4-amino-n-[2-(1h-imidazol-5-yl)ethyl]butanamide Chemical compound NCCCC(=O)NCCC1=CNC=N1 HXYUWNUJDSMLIE-UHFFFAOYSA-N 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 101500000018 Glycine max 2S albumin small chain Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010014095 Histidine decarboxylase Proteins 0.000 description 1
- 102100037095 Histidine decarboxylase Human genes 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- XWOBNBRUDDUEEY-UWVGGRQHSA-N Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 XWOBNBRUDDUEEY-UWVGGRQHSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- WXAYTPABEADAAB-UHFFFAOYSA-N Oxyphencyclimine hydrochloride Chemical compound Cl.CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 WXAYTPABEADAAB-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- BNQVUHQWZGTIBX-IUCAKERBSA-N Val-His Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC1=CN=CN1 BNQVUHQWZGTIBX-IUCAKERBSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 231100000987 absorbed dose Toxicity 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 150000004699 copper complex Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 208000014826 cranial nerve neuropathy Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010017314 prolyl dipeptidase Proteins 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 208000013363 skeletal muscle disease Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960003196 unithiol Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000003799 water insoluble solvent Substances 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- the present invention relates to a combination with a carnosinase inhibitor and an L-Lunosine and a composition therefor.
- the combination and composition of the carnosinase inhibitor and L-carnosine according to the present invention are useful in the fields of pharmaceutical fields, cosmetics, foods, and beverages. Background art
- Free radicals and the process of peroxidation caused by them are thought to be one of the causes of the decline in the structure and function of human and other mammalian tissues with age.
- natural antioxidants in various body tissues and in cells or in body fluids including plasma and bloodstream
- L-Lunosine (j3-alanyl-L-histidine) (I) is a non-protein fraction of vertebrate skeletal muscle (eg, Non-Patent Documents 1 and 2), other tissues such as olfactory epithelium and olfactory bulb (eg, It has been found to be one of the most abundant (112 mM) nitrogen compounds present in non-patent document 3) and lens (eg, non-patent document 4).
- L-Lunosine related natural products such as N-Acetyl-L-Lunosine, L-Anserine (/ 3-alanyl-L-3-Methylhistidine) and its N-Acetyl derivative, L-Valenine (J3—Aranil-L—1-Methyl His Titidine), L-homocarnosine (r-aminobutylyl L-histidine) and its N-acetyl derivative, and carcinine (/ 3-aralanylhistamine) (for example, Non-Patent Documents 5, 6, and 7)
- interesting differences in its distribution, activity, and metabolic transformation eg, Ref. 8
- millimolar concentrations in tissues such as skeletal muscle, heart, and brain of several mammals
- L-Lunosine and its related natural substances are the most important natural antioxidants in the lipid layer of cell membranes or biological membranes and in aqueous environments, lipids and proteins (including enzymes), DNA and other essential substances. It is known that a water-soluble molecule such as a molecule has an action of protecting an active oxygen species and a lipid peroxide from being damaged (for example, Non-Patent Documents 9, 10, 11, and 12).
- L-Lunosine and its naturally occurring related compounds include commercially available antioxidant enzymes such as SOD from cells and tissues, and dallastion and cellulopla It protects antioxidant systems like sumin from inactivation.
- Water-soluble L-Lunosine enhances the antioxidant action of lipid-soluble ⁇ -tocopherol during lipid peroxidation in liver microsomes. Therefore, L-Lunosine is a major protector of the liver cytochrome IV-450 system.
- L-Lunosine is the only antioxidant known to clearly protect cellular chromosomes from oxidative damage.
- antioxidant effects include atherosclerosis, ischemic disease (eg, cerebral infarction, transient ischemic attack, stroke, angina, myocardial infarction, etc.), the onset and progression of cataract, and aging of muscle and skin. It is considered useful for prevention.
- L-Linosine is also known to improve neurodegenerative diseases of the brain (eg, Alzheimer's disease, dementia, epilepsy, etc.).
- Non-Patent Document 15 L-carnosine supplementation is considered a useful method for prevention and treatment of such diseases.
- L-carnosine is the best anti-glycation agent discovered so far, and is known to inhibit the so-called Maillard reaction, that is, the advanced glycation reaction such as direct dilution of proteins and cross-linking of proteins. ing. Therefore, L-Lunosine is used not only for diabetic retinopathy, diabetic nephropathy, and dysuria, but also for vascular tissue aging (eg, arteriosclerosis, retinopathy, etc.), skin aging (eg, It can be expected to prevent aging of various tissues such as wrinkles) or aging of the lens (for example, cataract).
- Maillard reaction that is, the advanced glycation reaction such as direct dilution of proteins and cross-linking of proteins. ing. Therefore, L-Lunosine is used not only for diabetic retinopathy, diabetic nephropathy, and dysuria, but also for vascular tissue aging (eg, arteriosclerosis, retinopathy, etc.), skin
- Non-Patent Documents 16 and 17 Very recently, it has been reported that acrylamide, a carcinogenic and toxic substance, is formed in various foods by the Maillard reaction during cooking (eg, Non-Patent Documents 16 and 17). .
- L-carnosine has membrane stabilizing and tissue repairing effects, and is effective in preventing and treating gastrointestinal ulcer disease (eg, gastric ulcer, duodenal ulcer) or skin ulcer disease. It is also effective in treating wounds and burns.
- L-Lunosine and its related natural products have an anti-ischemic effect not only on the brain but also on the heart.
- L-Lunosine has been shown to increase the contractile power of the heart by increasing the cardiac cell's calcium response.
- L-Linosine injection has been shown to be effective in the emergency treatment of ischemic stroke.
- L-carnosine plays an important role in regulating acid-base balance in muscle when a large amount of H + is produced in conjunction with the accumulation of lactic acid due to intense exercise. Therefore, L-strength Lunosine plays a role in preventing muscle fatigue, which leads to improved exercise performance. L-Lunosine prevents muscle cell membranes from being oxidized under the acidic conditions of muscle movement. According to a recent report, the concentration of L-carnosine in muscle greatly correlates with average physical fitness (for example, Non-Patent Document 18).
- Lunosine L-strength Lunosine has been shown to dramatically improve the recovery from exercise-induced fatigue (however, it does not imply increased athletic performance, i.e., to enhance motility, but rather to facilitate anabolic responses to exercise) Is to close). Carnosine has been shown to rapidly restore muscle contractility following fatigue.
- L-Lunosine appears to be a real substrate for nitric oxide synthase (NOS).
- NOS nitric oxide synthase
- L-Lunosine supplementation stimulates the synthesis of the endogenous vasorelaxant nitric oxide (NO), which lowers blood pressure, prevents ischemic diseases such as angina, It is expected to improve erectile dysfunction in children.
- L-carnosine is effective as a scavenger for acetoaldehyde, a major product of ethanol metabolism when consuming alcoholic beverages (eg, whiskey, cognac, vodka, beer, liquor, wine, etc.) Patent Document 19). Therefore, L-carnosine can cause liver, brain or muscle to lose acetoaldehyde. Protects against toxicity. L-carnosine is also effective in treating and preventing gastrointestinal ulcers, which are aggravated by alcohol consumption, due to its wound healing properties.
- alcoholic beverages eg, whiskey, cognac, vodka, beer, liquor, wine, etc.
- L-Lunosine protects the brain not only from lipid peroxidation but also from the damage caused by excessive alcohol consumption.
- L-Lunosine has an immunostimulatory effect and protects the immune system from immunosuppression by hydrid cortisone, antitumor agents and many other immunosuppressants.
- L-carnosine has the following advantages to maintain health and youth.
- L-Lunosine and its related compounds may increase the number of cell divisions (the limit of Heyflick) and may be useful for prolonging survival or longevity (for example, Non-Patent Document 20).
- L-Lunosine has a rejuvenating effect on connective tissue cells and a wound healing effect. It has been reported that rejuvenation of cells approaching senescence can be achieved by maintaining cell division at a frequency that symbolizes youth and extending cell life. In tissue culture supplemented with L-carnosine, cells remained young and their survival was extended. This ability of L-Lunosine to increase cell survival also applies to senescent cells.
- exogenous carnosine is a typical example even when administered topically to the eye. Since it is easily excreted in urine or decomposed by an enzyme called carnosinase, it does not accumulate in tissues. This carnosine synthase is present in plasma, aqueous humor of the anterior chamber of the eye, liver, kidney and other tissues, and not in muscle (for example, Non-Patent Documents 21 and 22). Exists (for example, Non-Patent Documents 23 and 24).
- L-Lunosine-related natural substances such as N-Acetyl-L-Lunosine, L-Anserine, N-Acetyl-L-Anserine, L-Valenin, L-Homocarnosine, N-Acetyl-L-phomocarnosine or Carcinine are hydrolyzed Although the dissolution rate is slower than that of L-lunosine, it can be a substrate that is more or less hydrolyzed or inactivated by carnosinase (eg, Non-Patent Document 25).
- L-carnosine and Z or its related natural substances in the body due to aging or malnutrition causes various dysfunctions of the body in humans and other mammals. Supplementation with L-Lunosine or its related natural substances may therefore be useful in the treatment or prevention of such dysfunctions or diseases derived therefrom.
- oversupplementing L-Lunosine and Z or its related natural substances can help treat these diseases, improve athletic performance, prevent aging, treat skin, and improve quality of life (QOL). It is considered significant.
- L-Lunosine is already used in several countries as a dietary supplement or as a cosmetic, as mentioned above, L-Lunosine is facilitated by the enzyme so-called carnosinase (in two forms, serotype and tissue type). These products are not considered to be very effective as they are hydrolyzed to) 3-alanine and L-histidine, completely losing the physiological activity of L-l-Lunosine.
- Carnosine synthase is widely distributed in the lumen of the small intestine, plasma and other tissues of humans and other mammals, and, regardless of the method of oral, parenteral or topical administration, Treatment of diseases, improvement of motor skills, prevention of aging, skin care (skin care), improvement of QOL To achieve this, it is recommended that a large excess of L-Lunosine be administered to saturate the enzyme to prevent the administered L-Lunosine from being completely hydrolyzed.
- treatment with large excesses of L-Lunosine should be avoided not only from a practical and economic standpoint, but also from a safety standpoint, particularly due to the risk of histamine release in tissues and plasma.
- Non-patent document 1 K. G. Crush, Co. Immediately. Biochem. Physiol., Vol. 34, 3, 1970
- Non-patent document 2 A. A. Boldyrev, S.E. Sever in, Adv. Enzyme ReguL, Vol. 30, 175, 1990
- Non-Patent Document 3 F. Margolis, Science, Vol. 184, 909, 1974
- Non-Patent Document 4 Jay et al., Meeting Abstr. J. Physiol. London, Vol. 420, 155, 1990.
- Non-Patent Document 5 PR Carnegie et al., J. Chromatogr., -Vol. 261, 153, 1983 [Non-patent document 6] L. Flancbaum et al., Life Sci., Vol. 47, 1587, 1990 [Non-patent document 7] MA Babizhayev et al., Biochemistry (Moscow), Vol. 63, 620, 1998
- Non-patent document 8 MA Babizhayev et al., Biochem. J., Vol. 304, 509, 1994
- Non-patent document 9 MA Babizhayev ei al., Biochem. L, Vol. 304, 509, 1994
- Reference 10 MA Babizhayev et al., Biochemistry (Moscow), Vol. 63, 523, 1998
- Non-Patent Document 11 M.A.Babizhayev et al., Clinica Chimica Acta, Vol. 254, 1, 1996
- Non-Patent Document 12 J.H.Kang et al., Molecules and Cells, Vol. 13, 107, 2002
- Non-patent document 13 MA Babizhayev et al., Biochem. J., Vol. 304, 509, 1994
- Non-patent document 14 TA Dahl,. R. Midden, PE Hartman, Photochem. Photobiol., Vol. 47 , 357, 1988
- Non-Patent Document 15 Encephale, Vol. 28 (2), 147, 2002
- Non-patent document 16 DS Mot tram, et al, Nature, Vol.419, 448, 2002 [Non-patent document 17] RH Stadler, et al., Nature, Vol.419, 449, 2002 [Non-patent document 18] Y. Suzuki et al., Japan. J of Physiol., Vol. 64, 199, 2002
- Non-Patent Document 20 R. Hoi li day, G.A.McFarland., Biochemistry (Moscow), Vol. 65, 843, 2000)
- Non-patent document 21 Jackson et al., Clin. Chim. Acta, Vol. 196, 193, 1991
- Non-patent document 22 Lenney et al., Biochem. L, Vol. 228, 653, 1985
- Non-patent document 23 AA Boldyrev, AY Dupin, MA Babizhayev, SE Severin, Biochem. Int., Vol. 15, 1105, 1987
- Non-Patent Document 24 JL Jay et al., Meeting Abstr. J. Physiol. Lond., Vol. 420, 155, 1990.
- Non-Patent Document 25 A. Pegova et al., Comp. Biochem. Physiol. B. Biochem. Mol. Biol., Vol. 127 (4), 443, 2000.
- Non-Patent Document 26 SC Peppers, JF Lenney, Biol. Chem. Hoppe Seyler, Vol. 369, 1281, 1988 DISCLOSURE OF THE INVENTION-The present invention relates to a combination and a composition of a potent lunosinase inhibitor and an L-potency lunosine. It is useful for treating or preventing carnosine-related diseases, improving health, improving athletic performance, preventing aging, improving skin health, and preventing the side effects of alcoholic beverages.
- the present inventors have found that the combined use of L-carnosine and a carnosinase inhibitor is useful for treating or preventing carnosine-related diseases in mammals, and completed the present invention. It has also been found that such a combination or composition is useful for improving the health of mammals, improving athletic performance, preventing aging, improving skin health, and preventing the side effects of alcoholic beverages.
- a carnosinase inhibitor when a carnosinase inhibitor is simultaneously administered by the same route as the administration of L-potency lunosine, it is orally, parenterally or topically administered (skin, eye, oral mucosa, nasal mucosa, L-carnosine is effectively delivered to the plasma or target organ with very high bioavailability.
- parenterally or topically administered skin, eye, oral mucosa, nasal mucosa, L-carnosine is effectively delivered to the plasma or target organ with very high bioavailability.
- Any combination of administration routes and combination of each compound is possible. Such a combination can reduce the amount of L-Lunosine to be applied and significantly enhance the physiological effects of L-Lunosine.
- At least one of cellulose derivatives, gelatin and polyvinylpyrrolidone is added to these preparations.
- the present invention relates to such a new and effective method.
- the present invention relates to a novel chemotherapy for cancer, which comprises administering a tissue strength lunosinase inhibitor bestatin together with L-carnosine.
- a tissue strength lunosinase inhibitor bestatin it is known that Vesutin itself has an anticancer effect, but the present inventors have found that simultaneous administration with L-potency luminosine further improves the anticancer effect.
- increasing L-carnosine concentration in cancer cells prevents the division of malignant cancer cells without affecting normal cells.
- the precise molecular basis of L-carnosine's anticancer activity is correlated with the L-carnosine's phenic oxidase activity in malignant cancer cells.
- the blockade of the iron ion concentration in malignant cancer cells occurs, which induces apoptosis, that is, rapid death of the malignant cancer cells.
- bestatin (V) or an ester derivative thereof represented by the following formula is a carnosinase inhibitor useful not only for cancer chemotherapy but also for achieving the object of the present invention.
- R 2 represents a hydrogen atom or a lower alkyl group.
- the carnosynidase inhibitor is represented by the following formula: / 3-alanine (11), N-alkanoyl- / 3-alanine derivative (111), N-alkanoyl-L_carnosine derivative (IV) And at least one selected from the group consisting of vestibine and (V), and the combination according to any one of (1) to (4) above,
- R 2 independently represent a hydrogen atom or a lower alkyl group.
- R 2 represents a hydrogen atom or a lower alkyl group
- R 3 represents an alkyl group having 2 or more carbon atoms.
- R 2 represents a hydrogen atom or a lower alkyl group.
- the L-carnosine is L-carnosine, N-acetyl-L-l-lucinine, L-anserin, N-acetyl-L_anserin, L-parenin, L-homocarnosine, N-acetyl-L-
- (10) at least one selected from the group consisting of one amino acid derivative, one amino acid derivative, a thiol type reducing agent, a metal chelating agent, a hydrophobic vitamin having a branched hydrocarbon chain, manganese ion and zinc ion.
- a method for increasing the concentration of L-carnosine in plasma and cells which comprises using at least one carnosinase inhibitor selected from manganese ions and zinc ions.
- the L-Lunosine is L-Lunosine, ⁇ -acetyl-L-carnosine, ⁇ -acetyl-L-anserin, L-anserin, L-valenin, L-homocarnosine, ⁇ _acetyl-L_homo
- a pharmaceutical composition comprising:
- L-carnosine
- a health food composition or a dietary supplement composition characterized by containing
- a cosmetic or skin care composition comprising: a hydrophobic vitamin having a chain; and at least one carnosinase inhibitor selected from manganese ions and zinc ions.
- L-Lynosines;; 3-alanine (11), N-alkanoyl]] 3-alanine derivative (111), N-alkanoyl-L-carnosine derivative (IV), base ⁇ Contains at least one carnosinase inhibitor selected from human amino acid derivatives, amino acid derivatives, thiol-type reducing agents, metal chelating agents, hydrophobic vitamins having a branched hydrocarbon chain, manganese ion and zinc ion Alcoholic beverage composition, characterized by that
- the L-larnosines are L-carnosine, N-acetyl-L-carnosine, L-anserin, N-acetyl-L-anserin, L-valenin, L-homocarnosine, N-acetyl-L-
- R 2 independently represent a hydrogen atom or a linear or branched lower alkyl group, preferably a methyl group having 1 to 6 carbon atoms.
- R 2 independently represent a hydrogen atom or a linear or branched lower alkyl group, preferably a methyl group having 1 to 6 carbon atoms.
- R 3 is a linear or branched alkyl group having 2 or more carbon atoms, preferably 2 to 20 carbon atoms, that is, ethyl, propyl, isopropyl, butyl, Isobutyl, sec-butyl, tert-butyl, hexyl, heptyl, octyl, noel, decyl, pendecyl, dodecyl, tridecyl, tetradecyl, pendecyl, hexadecyl, Examples are heptane decyl, octadecyl, nonadecyl, eicosyl and the like.
- N-alkanoyl / 3-alanine derivatives (III) include N-formyl_] 3-alanine, N-acetyl-i3-alanine, N-propionyl-iS-alanine, N-butyryl-1- / 3-alanine, N- (2-methylpropionyl) -jS-alanine, N-pentanoyl i3-alanine, N-hexanoyl-1] 3-alanine, N-heptanoyl) 3-alanine, and their esters (eg, methyl ester, ethyl ester, etc.) A lower alkyl ester having 1 to 6 carbon atoms).
- N-acetyl-3 / 3-alanine is most preferable.
- the above N-alkanoyl] 3-alanine derivative ( ⁇ ⁇ ⁇ ) is a known compound or is prepared from) 3-alanine (II) by a known method using a known acylating agent or esterifying agent. be able to.
- N-alkanoyl-L-l-lunasine derivatives (IV) include N-l-pioneol L-l-lunosine, N- (2-methylpropionyl) -L-l-lunosine, N-butyryl-L-carnosine , N- (2-methylpropionyl) -L-L-carnosine, N-pentanoyl-L-carnosine, N-hexanoyl-L-carnosine, N-hepnoyl-L-carnosine and their esters (eg, methyl ester, ethyl ester And lower alkyl esters having 1 to 6 carbon atoms).
- esters eg, methyl ester, ethyl ester And lower alkyl esters having 1 to 6 carbon atoms.
- the above N-alkanoyl L-carnosine derivative (IV) is a known compound or uses a known acylating agent or esterifying agent. Can be produced from L-l-lunosin (I) in a manner known per se.
- Examples of the bestatins represented by the above formula (V) include bestatin and its ester.
- Examples of the ester include lower alkyl esters having 1 to 6 carbon atoms, such as methyl ester, ethyl ester, and propyl ester. These esters of vestin are known compounds or can be produced from vestatin in a manner known per se using known esterifying agents.
- Such compounds include monoamino acids and their derivatives (eg, L-alanine, L-mouth isine, L-isoleucine, L-parin, L-methionine, L-phenylalanine, N-acetyl-L-cysteine, N- Aminoacyl-L-histidine (eg G 1 yLH is, L-A la-L-His, L-Val-L-His, L-Leu-L-His, L-I1 e uLHis, L N-hydroxy-one amino acid; A-amino acid derivative (eg, amino-butyrylhistamine); Thiol-type reducing agent (eg, unitiol, dithiothreitol, 2-mercaptoethanol); manganese ion Zinc ion; prolinase substrate (eg, L-alanine, L-mouth isine, L-isoleucine, L-parin, L-methionine, L-phenylalanine
- hydrophobic vitamins having a branched hydrocarbon chain such as vitamin A and vitamin E, can be used as carnosinase inhibitors.
- L-active lunosine which is one of the active ingredients according to the combination of the present invention
- the acyl derivative is a known acylating agent using a known acylating agent. It can be manufactured by a method.
- L-carnosine is the major source of jS-alanine in the human body, its hydrolytic degradation is metabolically important. In humans, this hydrolysis reaction is catalyzed by two isozymes: tissue (cytoplasmic) carnosinase and serum carnosinase.
- tissue (cytoplasmic) carnosinase is a zinc-dependent meta-mouth protein, which is interestingly stabilized by other divalent metal cations. Therefore, when zinc (II) in the enzyme is replaced by another divalent metal cation, the enzyme activity in vitro is maintained or increased.
- the order of apparent activity effects of these divalent metal cations is Cd (II)> Mn (II) »Zn (II)> Co (II).
- enzymes activated by Mn (II) are inhibited by cations that originally function as activators (for example, Zn (11), Co (ID), and are inhibited by cations such as Be (II) and Fe (II).
- Cu (II) does not inhibit the enzyme due to the stability of the copper complex of the substrate, and therefore, for nutritional purposes, oral L-carnosine and Zn Combination with (II) or Mn (II) may be the easiest way to prevent L-Lunosine from being hydrolyzed by tissue or serum carnosinase.
- oral doses of about 40 Omg per day of L-Lunosine or other related natural derivatives (eg, anserine or varenin) mixed with about 5 mg of Zn (II) or Mn (II) can generally be given to adults.
- Vita Min E (40-100 I U) can be added to the oral formulation to increase the bioavailability of L-Lunosine.
- the carnosinase inhibitor II, II, IV, V or other compound can be administered at the same time as the L-carnosine or immediately before or immediately after the administration of the L-carnosine. Also, these compounds can be administered as a combined composition.
- the carnosinase inhibitor and L-l-Lunosine or compositions containing them may be used in the form of powders, granules, capsules, tablets, injections, infusions, troches, solutions, ointments, cataplasms It can be administered in appropriate dosage forms, such as mouthwashes, creams, sprays, nasal sprays, nasal drops, eye drops, suppositories and the like. These preparations can be produced according to a method known per se by appropriately adding selected additives and diluents.
- sugars such as water, sucrose, sorbitol, and fructose
- glycols such as polyethylene glycol and propylene glycol
- oils such as sesame oil, olive oil, and soybean oil
- Pharmaceutical additives such as preservatives such as P-hydroxybenzoic acid esters can be used.
- excipients such as lactose, glucose, sucrose, mannitol
- disintegrants such as starch and sodium alginate
- magnesium stearate Lubricants such as talc
- binders such as polyvinyl alcohol, hydroxypropyl cellulose and gelatin
- surfactants such as fatty acid esters
- plasticizers such as glycerin.
- preparations suitable for parenteral administration such as injections and drops can be prepared preferably using an aqueous medium isotonic with a body fluid.
- the injection can be prepared as a solution, suspension or dispersion using an aqueous medium selected from a salt solution, a glucose solution or a mixture of a salt solution and a glucose solution together with a suitable auxiliary according to a conventional method.
- eye drops can be prepared using a water-soluble solvent such as sterilized purified water or physiological saline, or a water-insoluble solvent such as vegetable oil.
- Suppositories for enteral administration can be prepared using carriers such as, for example, cocoa butter, hydrogenated fats or hydrogenated rugonic acid.
- Sprays can be prepared using a carrier which does not irritate the oral cavity and respiratory tract mucosa and which can promote absorption by dispersing the compound of the present invention as an active ingredient as fine particles.
- a carrier for example, lactose or dalyserin can be used.
- it can be prepared as a preparation in the form of an air sol / dry powder.
- parenteral preparations for example, one or more selected from diluents, fragrances, preservatives, excipients, disintegrants, lubricants, binders, surfactants, plasticizers, etc.
- Pharmaceutical additives can be used for example, one or more selected from diluents, fragrances, preservatives, excipients, disintegrants, lubricants, binders, surfactants, plasticizers, etc.
- Pharmaceutical additives can be used.
- the medicament according to the present invention can also be made into an ointment by mixing the above compound with a suitable base material.
- a suitable base material examples include oil-based bases such as petrolatum, liquid paraffin, silicon, and vegetable oil; bases such as hydrophilic baseline and purified lanolin; and emulsion bases such as macrogol. No.
- the ointment may contain an emulsifier such as an anionic or nonionic surfactant or a preservative such as paraoxybenzoic acid esters.
- the medicament according to the present invention includes, for example, transdermal patches, cataplasms, creams, plasters, tapes, lotions, solutions, suspensions, emulsions, sprays, etc. It can also be a preparation for administration.
- At least one type of composition selected from a cellulose derivative (for example, hydroxypropylcellulose), gelatin, and polyvinylpyrrolidone according to the present invention is used.
- a cellulose derivative for example, hydroxypropylcellulose
- gelatin for example, gelatin
- polyvinylpyrrolidone a cellulose derivative selected from a cellulose derivative (for example, hydroxypropylcellulose), gelatin, and polyvinylpyrrolidone according to the present invention.
- L-carnosine and carnosinase inhibitors can be added to alcoholic beverages (eg, whiskey, cognac, vodka, beer, liquor, wine, etc.), and alcoholic beverages can be added to the intestinal tract, liver, muscle, brain, etc. Can be protected from various obstacles.
- alcoholic beverages eg, whiskey, cognac, vodka, beer, liquor, wine, etc.
- alcoholic beverages can be added to the intestinal tract, liver, muscle, brain, etc. Can be protected from various obstacles.
- the daily dose of L_carnosine varies depending on the purpose of use and the method of administration, but the oral dose is generally about 0.1 l O OmgZkg, preferably about 0.5 ⁇ : LO OmgZkg, more preferably 1 l O OmgZkg. It is in the range of ⁇ 50 mg gZ kg. The dose can be divided into several times a day if necessary. Dosage for injection or infusion is usually 1Z5 to 1Z20 of oral dose. In the case of topical formulations, L-Lunosine is about 0.1-20% (w / w), preferably about 0.5-10% (w / w), more preferably about 1-5%. (w / w) Included in drug product.
- the amount of the carnosinase inhibitor used at the same time is about 0.1 to 20 molar equivalents, preferably 0.5 to 10 molar equivalents, more preferably about 1 to 5 molar equivalents, per mol of L-carnosine.
- the dosages of L-Lunosines and carnosinase inhibitors for mammals other than humans are the same as the dosages for humans described above.
- L-Lunosines administered to humans and other mammals can be effectively delivered to plasma, target organs or other organs without undergoing carnosinase degradation.
- a partially purified 0.1 M phosphate buffer of tissue carnosinase (pH 7.0) was prepared by a known method from a crude extract of male hairless rat brain (see: Y. Cour bebaisse, G.). Langrand, JF. Nicolay and MA Babizhayev, Proceeding of 19th IFSCC Congress, Australia, Vol. 3, 1996, p. 12; MA Babizhayev et al., Letters in Peptide Science, Vol. 5, 163, 1998). Incubate with substrate solution (450 M 1) in 0.1 M phosphate buffer (pH 7.0) with enzyme solution (501) diluted in the presence or absence of carnosinidase inhibitor at 37 ° C for 120 minutes did.
- the rate of hydrolysis is as follows.
- the concentration of / 3-alanine and L-carnosine in plasma and muscle can be determined by known methods (see: IJ0, Dowd et al., Biochim. Biophys. Acta, Vol. 967, 241, 1988; M. Dunne tt). and RC Harris, J. Chromatography B, Vol. 688, 47, 1997). ) The area under the blood concentration-time curve (AU C) for S-alanine and t -carnosine was calculated as an indicator of absorbed dose.
- Carnosine concentration in muscle fiber was 60.5-105.5 mmo 1 e / kg (weight of freeze-dried muscle sample of horses fed L-carnosine [mean value SD (corresponding to mean value of 46%)) ] To 88.9-125.5 mmo 1 e / kg (] 3-weight of freeze-dried muscle sample of horses fed alanine + L-carnosin) [Average soil SD (corresponding to an average of 4-6%) In each group, four out of five animals had a statistically significant difference (P ⁇ 0.05) in each of the four animals.
- the imidazole-containing dipeptide (pK a 6.8-7.1) acts like an important H + buffer over a range of physiological pH values (see RC Harris et al., Comp. Biochem. Physiol., Vo 1.97A, 249, 1990). Therefore, the higher the concentration of L-Lunosine in muscle fibers, the higher the H + tolerance, ie, the greater the buffering effect (see: M. Dunnett and RC Harris, J. Chromatography B, Vol. 688). : 47, 1997). Oral administration of L-Lunosine in combination with the carnosinase inhibitor / 3-alanine is a suitable method for increasing the concentration of imidazole-containing dipeptide, L-Lunosine, in muscle tissue.
- Example 3 Induction of Apoptosis in Cancer Cells by Combination of Carnosinase Inhibitor and L-Lunosine
- Vodka Extra Vodka Corn
- i3-alanine was added to the vodka with vigorous stirring so that the concentration of each became 70 mg / 200 g.
- the taste and euphoria of wok power remain unchanged and have been relished for 20 days by managers of this factory who regularly taste vodka, but have observed side effects such as headaches and liver toxicity Was not done.
- Five subjects drank 200 g of the mixed vodka daily.
- Urinary acetoaldehyde or malonaldehyde concentration 1 hour after drinking the drink in the morning on the last day of the test on day 20 of the test, as compared to the pre-test values of the test subjects I didn't.
- L-Ichi-Lunosine and /3.-alanine were administered as a mixture to seven gingivitis patients.
- the combination of L-Lunosine and / 3-alanine was found to promote gingival tissue healing and complete hemostasis, and reduced the gingival inflammatory response.
- the carnosin (5 mg / ml) +] 3-alanine (7 mg Zml) composition significantly increased granulation in gingival tissues.
- Use of L-Lunosine alone for gingival tissue Wound healing data has already been reported (see: K. Nagai, Langenbecks Arch. Chir., Vol. 351, 39, 1980; T. Yamane et al., J. Nihon Univ. School. Dent., Vol. 19, 70, 1977) 0
- Example 6 Mixture application of L-Lunosine and L-Lunosinase inhibitor 0-alanin as tan pigment product in cosmetic composition
- This composition can induce pigment compatibility on dark brown hair, blond hair and dyed hair, or on the skin.
- the cosmetic composition of L-Lunosine and 3-alanine was heated with the phospholipid lecithin to produce a pigment that tanned the skin to a tan color.
- Alanine is not colored in solution by itself, but develops color on reaction with tyrosine and cinnamate mono-oxidized cinnamate, dopa or dopamine.
- lecithin derived from egg yolk phosphatidylcholine
- lecithin derived from egg yolk phosphatidylcholine
- the ribosome was prepared from an emulsion of phospholipids in a phosphate buffer loaded with the compound by a slightly modified method comprising simultaneously two steps of a step of mixing heptane and buffer and a step of removing an organic solvent.
- 100 mg of phosphatidylcholine was dissolved in 15 ml of heptane in a round-bottom flask and 0.1 mol (or lower concentration) of PBS buffer (pH 7.4; 5 ml) was added.
- the lipophilic spots associated with aging disappear from the skin, and the color of the skin is smoothened to tan.
- Such dye compatibility was demonstrated.
- the spots were initially seen in the subject, but the treatment turned a smooth tan.
- Skin fluorescence in the blue-green region was reduced, and the nice and crisp skin appearance was increased.
- the excitation and emission spectra of the fluorescence at an excitation wavelength of 365 nm were monitored together, the fluorescence intensity of the pigment with lipogen decreased.
- Subjects who received the treatment reported that they had reduced senile lipogenous spots previously seen on the skin.
- the following ingredients are contained in one gelatin or rice capsule.
- Ophthalmic preparations treatment of eye disorders due to oxidative stress
- An object of the present invention is to provide a combination of a carnosinase inhibitor and L-carnosine and a composition therefor, which are useful for preventing disease and improving health. Further, the present invention provides a method for treating or preventing a carnosine-related disease in mammals, a method for improving health, a method for improving athletic performance, a method for improving skin health, and an alcohol beverage comprising a combination of a carnosinase inhibitor and an L-potency lunosine. It provides a way to prevent side effects and is useful in the fields of pharmaceuticals, cosmetics, health foods, foods and beverages.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Psychology (AREA)
- Mycology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/542,109 US20060116328A1 (en) | 2003-01-20 | 2004-01-16 | Combined use of carnosinase inhibitor with l-carnosines and composition |
JP2005508063A JPWO2004064866A1 (ja) | 2003-01-20 | 2004-01-16 | カルノシナーゼ阻害剤とl−カルノシン類との併用および組成物 |
EP04702856A EP1586332A4 (en) | 2003-01-20 | 2004-01-16 | COMBINED USE OF CARNOSINAS INHIBITOR WITH L-CARNOSINES AND COMPOSITION |
US14/094,155 US20140086855A1 (en) | 2003-01-20 | 2013-12-02 | Combined use of a carnosinase inhibitor with l-carnosine or its related substance and a composition containing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-10639 | 2003-01-20 | ||
JP2003010639 | 2003-01-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/542,109 A-371-Of-International US20060116328A1 (en) | 2003-01-20 | 2004-01-16 | Combined use of carnosinase inhibitor with l-carnosines and composition |
US14/094,155 Division US20140086855A1 (en) | 2003-01-20 | 2013-12-02 | Combined use of a carnosinase inhibitor with l-carnosine or its related substance and a composition containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004064866A1 true WO2004064866A1 (ja) | 2004-08-05 |
Family
ID=32767262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/000351 WO2004064866A1 (ja) | 2003-01-20 | 2004-01-16 | カルノシナーゼ阻害剤とl−カルノシン類との併用および組成物 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20060116328A1 (ja) |
EP (1) | EP1586332A4 (ja) |
JP (3) | JPWO2004064866A1 (ja) |
WO (1) | WO2004064866A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1506776A1 (de) * | 2003-08-12 | 2005-02-16 | KeyNeurotek AG | Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention von chronischen neurodegenerativen Erkrankungen |
WO2006120941A1 (ja) * | 2005-05-09 | 2006-11-16 | Shiseido Company, Ltd. | 不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物 |
JP2009120564A (ja) * | 2007-11-16 | 2009-06-04 | Maruha Nichiro Foods Inc | ヒアルロン酸産生促進物質 |
WO2010005077A1 (ja) * | 2008-07-11 | 2010-01-14 | 財団法人ヒューマンサイエンス振興財団 | パーキンソン病の疾患関連たんぱく質およびその使用 |
US7776364B2 (en) | 2006-03-24 | 2010-08-17 | Advanced Scientific, Llc | Non-surgical method for treating cataracts in mammals including man |
JP2010208989A (ja) * | 2009-03-10 | 2010-09-24 | Fancl Corp | 抗不安剤 |
WO2011078204A1 (ja) * | 2009-12-24 | 2011-06-30 | 浜理薬品工業株式会社 | 高脂血症の予防または治療剤、および抗疲労剤 |
JP2012021026A (ja) * | 2011-10-07 | 2012-02-02 | Shiseido Co Ltd | 不全角化抑制剤、毛穴縮小剤及び肌荒れ防止・改善剤 |
JP2013176327A (ja) * | 2012-02-28 | 2013-09-09 | Sapporo Breweries Ltd | 麦芽飲料、香味改善剤及びこれらに関する方法 |
WO2014140890A2 (en) | 2013-03-13 | 2014-09-18 | Neocutis Sa | Peptides for skin rejuvenation and methods of using the same |
WO2017104777A1 (ja) * | 2015-12-16 | 2017-06-22 | サントリーホールディングス株式会社 | カルノシンジペプチダーゼ阻害用組成物 |
CN108578678A (zh) * | 2018-03-13 | 2018-09-28 | 孟斯琴 | 一种抗癫痫药物组合物及其制备方法 |
WO2022167569A1 (en) * | 2021-02-04 | 2022-08-11 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic composition |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007211625B2 (en) | 2006-02-01 | 2012-08-23 | Nestec S.A. | Nutritional system and methods for increasing longevity |
EP2486910A3 (en) * | 2006-10-27 | 2012-08-22 | The Curators Of The University Of Missouri | Multi-chambered apparatus comprising a dispenser head |
EP2052735B1 (en) | 2007-10-22 | 2016-05-11 | Lytone Enterprise, Inc. | Pharmaceutical composition and kit comprising anserine for rapidly reducing uric acid in blood |
US8802731B2 (en) * | 2011-04-13 | 2014-08-12 | Thermolife International, Llc | N-acetyl beta alanine methods of use |
ITMI20121586A1 (it) * | 2012-09-24 | 2014-03-25 | N G C Medical Spa | L-carnosina per il trattamento delle miopatia congenita mitocondriale e della sindrome della fatica muscolare cronica |
JP2016135746A (ja) * | 2015-01-23 | 2016-07-28 | 学校法人順天堂 | 新規トリペプチド及びそれを含有する医薬 |
TW201709924A (zh) * | 2015-07-16 | 2017-03-16 | Suntory Holdings Ltd | 含有來自動植物之胜肽的血清肌肽分解酵素阻礙用組成物 |
WO2017010537A1 (ja) * | 2015-07-16 | 2017-01-19 | サントリーホールディングス株式会社 | 環状ジペプチド含有血清カルノシン分解酵素阻害用組成物 |
CN105461632B (zh) * | 2016-01-04 | 2018-01-09 | 湖北泓肽生物科技有限公司 | 一种n‑乙酰‑l‑肌肽的制备方法 |
JP2020031556A (ja) * | 2018-08-28 | 2020-03-05 | 浜理薬品工業株式会社 | 筋損傷抑制剤 |
US11865139B2 (en) | 2020-11-12 | 2024-01-09 | Thermolife International, Llc | Method of treating migraines and headaches |
CN112870182A (zh) * | 2021-03-18 | 2021-06-01 | 中南大学 | 紫苏醇及其衍生物在制备减轻化疗副作用药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58164516A (ja) * | 1982-03-25 | 1983-09-29 | Kaneshiro Nagai | 湿疹性皮膚疾患および薬疹治療剤 |
JPS58164511A (ja) * | 1982-03-25 | 1983-09-29 | Kaneshiro Nagai | 老人性▲そう▼痒症の治療剤 |
WO1996036348A1 (en) * | 1995-05-19 | 1996-11-21 | Farmila-Farmaceutici Milano S.R.L. | Pharmaceutical and/or dietetic compositions with antioxidant activity containing carnosine or derivatives and branched amino acids |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6314728A (ja) * | 1986-07-03 | 1988-01-21 | Zeria Shinyaku Kogyo Kk | 肝障害の予防、治療剤 |
US4837012A (en) * | 1987-06-19 | 1989-06-06 | S. C. Johnson & Son, Inc. | Hair reviver composition containing film-forming amino acids |
JP2811353B2 (ja) * | 1990-07-06 | 1998-10-15 | ゼリア新薬工業株式会社 | 炎症性腸疾患予防・治療剤 |
FR2701948B1 (fr) | 1993-02-22 | 1996-07-26 | Exsymol Sa | Produit de couplage de l'histamine ou l'histamine méthyl-substituée et d'un acide aminé, procédé de préparation et applications thérapeutiques, cosmétologiques et agroalimentaires. |
IT1270905B (it) * | 1993-10-15 | 1997-05-13 | Bruschettini Srl | Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta |
US5965596A (en) * | 1997-08-12 | 1999-10-12 | Harris; Roger | Methods and compositions for increasing the anaerobic working capacity in tissue |
JPH1112191A (ja) | 1997-06-24 | 1999-01-19 | Hamari Yakuhin Kogyo Kk | エタノール吸収阻害剤 |
WO2003088947A1 (en) * | 2002-04-22 | 2003-10-30 | Experimental & Applied Sciences, Inc. | Food supplements containing 4-hydroxyisoleucine and creatine |
EP1551399A4 (en) * | 2002-09-30 | 2011-01-05 | Mark A Babizhayev | METHOD FOR THE TOPICAL TREATMENT OF EYE DISEASES AND COMPOSITION AND DEVICE FOR THIS TREATMENT |
US6899904B2 (en) * | 2002-11-14 | 2005-05-31 | The Meow Mix Company | Pet food compositions having electrostatically charged ingredient |
-
2004
- 2004-01-16 JP JP2005508063A patent/JPWO2004064866A1/ja active Pending
- 2004-01-16 WO PCT/JP2004/000351 patent/WO2004064866A1/ja active Application Filing
- 2004-01-16 US US10/542,109 patent/US20060116328A1/en not_active Abandoned
- 2004-01-16 EP EP04702856A patent/EP1586332A4/en not_active Withdrawn
-
2010
- 2010-10-22 JP JP2010237838A patent/JP2011068652A/ja active Pending
-
2013
- 2013-10-07 JP JP2013210364A patent/JP2014012735A/ja active Pending
- 2013-12-02 US US14/094,155 patent/US20140086855A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58164516A (ja) * | 1982-03-25 | 1983-09-29 | Kaneshiro Nagai | 湿疹性皮膚疾患および薬疹治療剤 |
JPS58164511A (ja) * | 1982-03-25 | 1983-09-29 | Kaneshiro Nagai | 老人性▲そう▼痒症の治療剤 |
WO1996036348A1 (en) * | 1995-05-19 | 1996-11-21 | Farmila-Farmaceutici Milano S.R.L. | Pharmaceutical and/or dietetic compositions with antioxidant activity containing carnosine or derivatives and branched amino acids |
Non-Patent Citations (37)
Title |
---|
A. PEGOVA ET AL., COMP. BIOCHEM. PHYSIOL. B. BIOCHEM. MOL. BIOL., vol. 127, no. 4, 2000, pages 443 |
A.A. BOLDYREV, A.Y. DUPIN, M.A. BABIZHAYEV, S.E. SEVERIN, BIOCHEM. INT., vol. 15, 1987, pages 1105 |
A.A. BOLDYREV, S.E. SEVERIN, ADV. ENZYME REGUL., vol. 30, 1990, pages 175 |
ANN. NY ACAD. SCI., vol. 854, 1998, pages 37 |
BABIZHAYEV M.A.: "Antioxidant activity of L-carnosine, a natural histidine-containing dipeptide in crystalline lens", BIOCHIM. BIOPHYS. ACTA, vol. 1004, 1989, pages 363 - 371, XP023577765, DOI: doi:10.1016/0005-2760(89)90085-4 |
D.S. MOTTRAM ET AL., NATURE, vol. 419, 2002, pages 448 |
ENCEPHALE, vol. 28, no. 2, 2002, pages 147 |
F. MARGOLIS, SCIENCE, vol. 184, 1974, pages 909 |
J.H. KANG ET AL., MOLECULES AND CELLS, vol. 13, 2002, pages 107 |
J.J. O'DOWD ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 967, 1988, pages 241 |
J.L. JAY ET AL., MEETING ABSTR. J. PHYSIOL. LOND., vol. 420, 1990, pages 155 |
JACKSON ET AL., CLIN. CHIM. ACTA, vol. 196, 1991, pages 193 |
JAY ET AL., MEETING ABSTR. J. PHYSIOL., vol. 420, 1990, pages 155 |
K. NAGAI, LANGENBECKS ARCH. CHIR., vol. 351, 1980, pages 39 |
K.G.CRUSH, COMP. BIOCHEM. PHYSIOL., vol. 34, 1970, pages 3 |
L . FLANCBAUM ET AL., LIFE SCI., vol. 47, 1990, pages 1587 |
LENNEY ET AL., BIOCHEM. J., vol. 228, 1985, pages 653 |
LENNEY J.F. ET AL: "Human Cytosolic Carnosinase: Evidence of Identity with Prolinase, a Non-specific Dipeptidase", BIOLOGICAL CHEMISTRY HOPPE-SEYLER, vol. 371, no. 2, 1990, pages 167 - 171, XP002979351 * |
M. A. BABIZHAYEV ET AL., BIOCHEM. J., vol. 304, 1994, pages 509 |
M. DUNNETT, R.C. HARRIS, J. CHROMATOGRAPHY B, vol. 688, 1997, pages 47 |
M.A. BABIZHAYEV ET AL., BIOCHEM. J., vol. 304, 1994, pages 509 |
M.A. BABIZHAYEV ET AL., BIOCHEMISTRY (MOSCOW, vol. 63, 1998, pages 523 |
M.A. BABIZHAYEV ET AL., BIOCHEMISTRY (MOSCOW, vol. 63, 1998, pages 620 |
M.A. BABIZHAYEV ET AL., CLINICA CHIMICA ACTA, vol. 254, 1996, pages 1 |
M.A. BABIZHAYEV ET AL., LETTERS IN PEPTIDE SCIENCE, vol. 5, 1998, pages 163 |
M.C. JACKSON ET AL., CLIN. CHIM. ACTA, vol. 196, 1991, pages 193 |
P.R. CARNEGIE ET AL., J. CHROMATOGR., vol. 261, 1983, pages 153 |
PEPPERS S.C. ET AL: "Bestatin Inhibition of Human Tissue Carnosinase, a Non-Specific Cytosolic Dipeptidase", BIOLOGICAL CHEMISTRY HOPPE-SEYLER, vol. 369, no. 12, 1988, pages 1281 - 1286, XP002979350 * |
R. HOLLIDAY, G.A. MCFARLAND., BIOCHEMISTRY (MOSCOW, vol. 65, 2000, pages 843 |
R.C. HARRIS ET AL., COMP. BIOCHEM. PHYSIOL., vol. 97A, 1990, pages 249 |
R.H. STADLER ET AL., NATURE, vol. 419, 2002, pages 449 |
S.C. PEPPERS, J.F. LENNEY, BIOL. CHEM. HOPPE SEYLER, vol. 369, 1988, pages 1281 |
SEKINE ET AL., INT. J. CANCER, vol. 94, 2001, pages 485 |
T. YAMANE ET AL., J. NIHON UNIV. SCHOOL. DENT., vol. 19, 1977, pages 70 |
T.A. DAHL, W.R. MIDDEN, P.E. HARTMAN, PHOTOCHEM. PHOTOBIOL., vol. 47, 1988, pages 357 |
Y. COURBEBAISSE, G. LANGRAND, J-F. NICOLAY, M.A. BABIZHAYEV, PROCEEDING OF 19TH IFSCC CONGRESS, vol. 3, 1996, pages 1 - 12 |
Y. SUZUKI ET AL., JAPAN. J OF PHYSIOL., vol. 64, 2002, pages 199 |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291599B2 (en) | 2003-08-12 | 2007-11-06 | Keyneurotek Ag | Use of inhibitors of enzymes having activities of amino peptidase N and/or dipeptidyl peptidase IV and of pharmaceutical preparations thereof for a therapy and prevention of chronical neurodegenerative diseases |
EP1506776A1 (de) * | 2003-08-12 | 2005-02-16 | KeyNeurotek AG | Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention von chronischen neurodegenerativen Erkrankungen |
CN101175470B (zh) * | 2005-05-09 | 2011-09-14 | 株式会社资生堂 | 角化不全抑制剂、毛孔收缩剂和皮肤外用组合物 |
WO2006120941A1 (ja) * | 2005-05-09 | 2006-11-16 | Shiseido Company, Ltd. | 不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物 |
JP2006312597A (ja) * | 2005-05-09 | 2006-11-16 | Shiseido Co Ltd | 不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物 |
US8937090B2 (en) | 2005-05-09 | 2015-01-20 | Shiseido Company, Ltd. | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin |
KR101338982B1 (ko) * | 2005-05-09 | 2013-12-10 | 가부시키가이샤 시세이도 | 부전각화 억제제, 모공 축소제 및 피부 외용 조성물 |
US7776364B2 (en) | 2006-03-24 | 2010-08-17 | Advanced Scientific, Llc | Non-surgical method for treating cataracts in mammals including man |
JP2009120564A (ja) * | 2007-11-16 | 2009-06-04 | Maruha Nichiro Foods Inc | ヒアルロン酸産生促進物質 |
WO2010005077A1 (ja) * | 2008-07-11 | 2010-01-14 | 財団法人ヒューマンサイエンス振興財団 | パーキンソン病の疾患関連たんぱく質およびその使用 |
JP2010208989A (ja) * | 2009-03-10 | 2010-09-24 | Fancl Corp | 抗不安剤 |
JPWO2011078204A1 (ja) * | 2009-12-24 | 2013-05-09 | 浜理薬品工業株式会社 | 高脂血症の予防または治療剤、および抗疲労剤 |
WO2011078204A1 (ja) * | 2009-12-24 | 2011-06-30 | 浜理薬品工業株式会社 | 高脂血症の予防または治療剤、および抗疲労剤 |
JP2012021026A (ja) * | 2011-10-07 | 2012-02-02 | Shiseido Co Ltd | 不全角化抑制剤、毛穴縮小剤及び肌荒れ防止・改善剤 |
JP2013176327A (ja) * | 2012-02-28 | 2013-09-09 | Sapporo Breweries Ltd | 麦芽飲料、香味改善剤及びこれらに関する方法 |
US9375398B2 (en) | 2013-03-13 | 2016-06-28 | Neocutis S.A. | Peptides for skin rejuvenation and methods of using the same |
WO2014140890A2 (en) | 2013-03-13 | 2014-09-18 | Neocutis Sa | Peptides for skin rejuvenation and methods of using the same |
US10543195B2 (en) | 2013-03-13 | 2020-01-28 | Anteis Sa | Peptides for skin rejuvenation and methods of using the same |
US11331305B2 (en) | 2013-03-13 | 2022-05-17 | Anteis Sa | Peptides for skin rejuvenation and methods of using the same |
WO2017104777A1 (ja) * | 2015-12-16 | 2017-06-22 | サントリーホールディングス株式会社 | カルノシンジペプチダーゼ阻害用組成物 |
JPWO2017104777A1 (ja) * | 2015-12-16 | 2018-10-04 | サントリーホールディングス株式会社 | カルノシンジペプチダーゼ阻害用組成物 |
CN108578678A (zh) * | 2018-03-13 | 2018-09-28 | 孟斯琴 | 一种抗癫痫药物组合物及其制备方法 |
WO2022167569A1 (en) * | 2021-02-04 | 2022-08-11 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic composition |
Also Published As
Publication number | Publication date |
---|---|
EP1586332A1 (en) | 2005-10-19 |
JP2011068652A (ja) | 2011-04-07 |
US20140086855A1 (en) | 2014-03-27 |
US20060116328A1 (en) | 2006-06-01 |
JP2014012735A (ja) | 2014-01-23 |
JPWO2004064866A1 (ja) | 2006-05-18 |
EP1586332A4 (en) | 2009-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014012735A (ja) | カルノシナーゼ阻害剤とl−カルノシン類との併用および組成物 | |
Packer | Interactions among antioxidants in health and disease: vitamin E and its redox cycle | |
KR100617929B1 (ko) | 환원된 조효소 q 의 안정한 용액 | |
TWI245628B (en) | Stabilized composition of reduced coenzyme Q10 aqueous solution | |
US20060228395A1 (en) | Vitamin E phosphate/phosphatidylcholine liposomes to protect from or ameliorate cell damage | |
KR100489371B1 (ko) | 산화성스트레스로발생한심혈관계및신경계통질환의예방과치료에유용한l-카르니틴,이들의유도체및항산화제의용도 | |
WO2011078204A1 (ja) | 高脂血症の予防または治療剤、および抗疲労剤 | |
US20100061969A1 (en) | Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic | |
US20190142885A1 (en) | Antioxidant composition comprising sargassum serratifolium extract or fraction thereof as active ingredient | |
US20050181021A1 (en) | Vitamin E phosphate/phosphatidycholine liposomes to protect from or ameliorate cell damage | |
RU2288707C2 (ru) | Антиатеросклеротическая композиция, содержащая каротиноиды, и способ ингибирования окисления липопротеина низкой плотности (ldl) | |
EP2136777A2 (fr) | Utilisation de la citrulline pour le traitement de pathologies liees a une augmentation de la carbonylation des proteines | |
US6576266B1 (en) | Plant extract based on glycerides, a method for the preparation of this extract and a cosmetic composition containing the same | |
WO1993015731A1 (en) | Phosphate derivatives of vitamin e to protect cells from effects of aging and injury | |
WO2005099739A1 (en) | Oxygenated dibenzo-alpha-pyrone chromoproteins | |
KR101072198B1 (ko) | 피부 미백용 화장료 조성물 | |
FR3091161A1 (fr) | Extrait de chlamydomonas acidophila, son procede de preparation et les compositions cosmetiques, et dermatologiques le comprenant | |
WO2001012141A1 (fr) | Stimulants pour la pousse de cheveux | |
Biagi et al. | The effect of dietary polyenylphosphatidylcholine on microsomal delta-6-desaturase activity, fatty acid composition, and microviscosity in rat liver under oxidative stress | |
EP2452577B1 (fr) | Solution aqueuse de phytine et utilisation de ladite solution pour la préparation d'un complément alimentaire liquide ou d'une composition cosmétique | |
KR20090119085A (ko) | 안토시아닌을 포함하는 자외선 조사에 의해 유도된아팝토시스 억제용 조성물 | |
JP5468758B2 (ja) | セラミド類含有組成物 | |
US20050233942A1 (en) | Oxygenated dibenzo-alpha-pyrone chromoproteins | |
KR20180011310A (ko) | 미백 화장료 조성물 | |
JP2000072686A (ja) | 活性酸素消去剤およびこれを含有する組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
REEP | Request for entry into the european phase |
Ref document number: 2004702856 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004702856 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006116328 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005508063 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10542109 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004702856 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10542109 Country of ref document: US |